Steroid Withdrawal in Pediatric Renal Transplant: Impact on Growth, Bone Metabolism and Acute Rejection
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The present study investigates the safety and efficacy of steroid withdrawal at six days
post-transplant in pediatric renal recipients under concomitant immunosuppression based on
antibodies anti IL2 (interleukin 2), Tacrolimus (TAC) and Mycophenolate Mofetil (MMF). To
investigate the impact of this protocol in growth, bone metabolism, insulin- sensitivity and
evaluate the expression of IL17 (interleukin 17) and mRNA FOXP3 (messenger ribonucleic acid
forkhead box protein 3) as early markers of acute rejection (blood, urine and renal biopsy).
Hypothesis:Steroid withdrawal in renal pediatric transplant patients improves growth and bone
metabolism without increasing the risk of acute rejection. The expression of FoxP3/IL17 in
urine cells could be an early molecular markers of acute rejection.
Phase:
Phase 3
Details
Lead Sponsor:
Fondo Nacional de Desarrollo Científico y Tecnológico, Chile